Related Experiment Video
Updated: Jul 31, 2026
08:08
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
16.4K
Extracellular vesicle proteomics in brain solid tumors: future strategy for personalized medicine
Sonia Spinelli1, Andrea Garbarino1, Marco Pavanello2
1Laboratory of Molecular Nephrology, Istituto Giannina Gaslini IRCCS, Genoa, Italy.
Expert Review of Proteomics
|May 30, 2025
Summary
Extracellular vesicles (EVs) proteomics offers a promising avenue for discovering brain tumor biomarkers. These EVs, collected non-invasively, reflect tumor metabolism and aid in diagnosis and prognosis.
Area of Science:
- Neuro-oncology
- Cancer biology
- Proteomics
Background:
- Brain solid tumors are a major cause of cancer mortality.
- The 2021 WHO CNS tumor classification relies on genomic diagnostics.
- Extracellular vesicles (EVs) proteomics is crucial for biomarker discovery in brain tumor management.
Purpose of the Study:
- Review recent proteomic studies (2022-2024) of EVs in brain tumor patients.
- Focus on studies investigating metabolic aspects of brain tumors.
- Highlight the role of EVs in reflecting tumor metabolic reprogramming.
Main Methods:
- Analysis of recent literature on EVs proteomics in brain tumors.
- Selection of studies focusing on metabolic aspects and recent publications.
- Minimally invasive collection of EVs from cerebrospinal fluid or blood for analysis.
Main Results:
- EVs proteomics can identify key biomarkers and therapy targets in CNS tumors.
- EVs reflect the metabolic adaptations of brain tumors.
- Metabolic dependencies identified through EVs can be potential therapeutic targets.
Conclusions:
- EVs proteomics is a promising platform for biomarker discovery in brain tumors.
- EV-based proteomic and metabolic analysis offers diagnostic and prognostic potential.
- This approach aids in managing brain solid tumors, a leading cause of cancer mortality.
